source
- U.S. proposes rule tightening review of biotech licensing deals with Chinese firmsThe U.S. is preparing to issue a proposed rule that would place additional scrutiny on outbound licensing agreements between American biotech firms and Chinese companies. The measure aims to increa…
- FDA approves GSK hepatitis B drug; EQT to acquire Qiagen for $10.8 billionThe U.S. Food and Drug Administration has granted approval to GlaxoSmithKline's new hepatitis B therapy, marking a regulatory milestone for the company. Private-equity firm EQT announced a definit…